Skip to main content
. 2014 Jul 29;143(1):42–51. doi: 10.1111/imm.12288

Figure 4.

Figure 4

Proposed model of rituximab (RTX)-mediated inhibition of the nuclear factor-κB (NF-κB) pathway in primary Sjögren syndrome salivary gland epithelial cells (pSS SGEC). The NF-κB signalling pathway is constitutively active in pSS SGEC and these cells express low levels of Raf-1 kinase inhibitor protein (RKIP). In a co-culture system with pSS lymphocytes, on ligation to CD20, RTX up-regulates RKIP expression. RKIP inhibits the activity of the NF-κB pathway, culminating in decreased expression of NF-κB-dependent pro-inflammatory genes.